financetom
Business
financetom
/
Business
/
Chevron Posts Q3 Beat As 'Uncertainty Around Hess Deal Remains,' Analysts Say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chevron Posts Q3 Beat As 'Uncertainty Around Hess Deal Remains,' Analysts Say
Nov 4, 2024 11:06 AM

Shares of Chevron Corp ( CVX ) continued to rise in early trading on Monday, after the company reported upbeat third-quarter results.

The San Ramon, California-based company reported its results amid an exciting earnings season. Here are some key analyst takeaways.

Truist Securities analyst Neal Dingmann maintained a Hold rating, while raising the price target from $150 to $155.

RBC Capital Markets analyst Biraj Borkhataria reiterated an Outperform rating, while lifting the price target from $170 to $175.

Scotiabank analyst Paul Cheng reaffirmed a Sector Outperform rating and price target of $163.

Check out other analyst stock ratings.

Truist Securities: Chevron's ( CVX ) third-quarter earnings came in ahead of consensus estimates, with production on a BOE (barrel of oil equivalent) basis topping expectations, although pricing was weaker than anticipated, Dingmann said. "Production benefited from strong growth in the Permian offset by the impacts of hurricanes," he added.

Margins at Chevron's ( CVX ) refinery business remained under pressure due to strong supply and "limited incremental demand for petroleum products," the analyst stated. While Chevron ( CVX ) is likely to generate "relatively minimal" earnings growth next year due to margin pressure and lower oil, a potential successful acquisition of Hess "would notably change our estimates," he further wrote.

RBC Capital Markets: Chevron ( CVX ) reported its earnings and cash flows ahead of expectation, backed by "a solid operational performance," Borkhataria said.

"Record production in the Permian, and strong delivery elsewhere supported CVX’s earnings this quarter, and the new structural cost reduction target should help investors re-focus on the investment case," the analyst wrote. While uncertainty around the Hess deal remains, management's commentary around Permian capex peaking in 2024 is likely to boost free cash flows into 2025 and beyond, he added.

Scotiabank: The company's adjusted earnings of $2.51 per share and cash flows of $4.59 per share beat consensus of $2.41 and $4.32, respectively. "Robust Upstream production drove the beat, with the company setting yet another quarterly record in the Permian and achieved record high production in TCO," Cheng said.

Chevron ( CVX ) repurchased $4.7 billion of stock in the third quarter, higher than the quarterly run-rate target of $4.375 billion at the midpoint, the analyst stated. The company aims at cost reduction between $2 billion and $3 billion by end of 2026, while targeting another $7 billion in assets sales by 2028, he added.

Price Action: Shares of Chevron ( CVX ) had risen by 0.48% to $153.81 at the time of publication on Monday.

Read More:

Stock Of The Day: Oil Climbs — And Chevron Follows Suit

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Remy Cointreau too concentrated in cognac, investors say
Remy Cointreau too concentrated in cognac, investors say
Jul 24, 2024
LONDON (Reuters) - Remy Cointreau investors say the company needs to diversify further as its reliance on cognac sales in the United States and China leaves it among the worst-hit by a global spirits downturn. The maker of Remy Martin cognac has already signalled it wants to grow sales in other markets and invest in its portfolio of other drinks,...
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
Jul 24, 2024
Sage Therapeutics Inc. ( SAGE )  and Biogen Inc. ( BIIB )  announced results Wednesday from the Phase 2 KINETIC 2 dose-range study of SAGE-324 (BIIB124) as a potential treatment for essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor...
-- New Gold Brief: Reporting Fatality at the Rainy River Mine
-- New Gold Brief: Reporting Fatality at the Rainy River Mine
Jul 24, 2024
11:15 AM EDT, 07/24/2024 (MT Newswires) -- Price: 3.14, Change: +0.11, Percent Change: +3.63 ...
Concentra Group Holdings Parent, Inc IPOs Tomorrow, Here's What You Need To Know
Concentra Group Holdings Parent, Inc IPOs Tomorrow, Here's What You Need To Know
Jul 24, 2024
Concentra Group Holdings Parent, Inc IPO will take place July, 25 on the NYSE exchange under the ticker CON. The company is offering shares at an expected price between $23.00 and $26.00 per share with an insider lock-up period of 180 days ending on January 21, 2025. See also: Benzinga IPO Calendar About Concentra Group Holdings Parent, Inc Concentra Group...
Copyright 2023-2026 - www.financetom.com All Rights Reserved